Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 386.00K | 4.15M | 6.98M | 9.94M | 8.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 386.00K | 4.15M | 6.98M | 9.94M | 8.80M |
| Cost of Revenue | 88.64M | 96.39M | 104.05M | 108.15M | 114.56M |
| Gross Profit | -88.25M | -92.24M | -97.07M | -98.22M | -105.77M |
| SG&A Expenses | 23.27M | 25.38M | 27.14M | 28.28M | 29.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.91M | 121.77M | 131.19M | 136.43M | 144.29M |
| Operating Income | -111.52M | -117.62M | -124.21M | -126.50M | -135.49M |
| Income Before Tax | -97.82M | -131.56M | -144.49M | -164.57M | -104.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.82 | -131.56 | -144.49 | -164.57 | -104.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.82M | -131.56M | -144.49M | -164.57M | -104.96M |
| EBIT | -111.52M | -117.62M | -124.21M | -126.50M | -135.49M |
| EBITDA | -110.18M | -116.00M | -122.26M | -124.25M | -132.89M |
| EPS Basic | -3.03 | -4.30 | -5.01 | -5.77 | -3.76 |
| Normalized Basic EPS | -1.89 | -2.63 | -3.07 | -3.55 | -2.30 |
| EPS Diluted | -3.03 | -4.30 | -5.01 | -5.77 | -3.76 |
| Normalized Diluted EPS | -1.89 | -2.63 | -3.07 | -3.55 | -2.30 |
| Average Basic Shares Outstanding | 147.13M | 135.78M | 124.42M | 113.29M | 111.67M |
| Average Diluted Shares Outstanding | 147.13M | 135.78M | 124.42M | 113.29M | 111.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |